M. Sherry Ku - Concepedia

Concepedia

Author

M. Sherry Ku

Critical Path Institute

Also Known As

M. Sherry Ku, MS Ku, Min-Hsi Ku, Minhoo Ku

17

Publications

1.2K

Citations

12

H-Index

27

Concepts

All Affiliations

Critical Path Institute Janssen (Belgium)United States Military Academy Bristol-Myers Squibb (United States)Roche (Switzerland)

MS

About

M. Sherry Ku is an author at Critical Path Institute specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.2K
2	Biostatistics	4	4	560
3	Biomedical Engineering	3	3	288
4	Engineering	2	2	227
5	Chemical Engineering	1	1	57

M. Sherry Ku

×

12

Publications

1.2K

Citations

12

H-Index

	Year	Citations
Use of the Biopharmaceutical Classification System in Early Drug Development M. Sherry Ku The AAPS Journal Preclinical Drug EvaluationBioanalysisPharmacologyDrug DevelopmentMedicine	2008	219
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison, Journal of Pharmaceutical Sciences Pharmacokinetic ModelingMedicineDrug DiscoveryPrediction MethodsPhrma Cpcdc Initiative	2011	198
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones, Journal of Pharmaceutical Sciences Precision DosingPhysiologically Based PharmacokineticsPharmacokinetic ModelingHuman PharmacokineticsMedicine	2011	170
A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept M. Sherry Ku, Wendy Dulin Pharmaceutical Development and Technology Pharmaceutical ScienceEngineeringProject Cycle TimeBona Fide FormulationsBiomedical Engineering	2010	170
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution Rhys D.O. Jones, Hannah M. Jones, Malcolm Rowland, Journal of Pharmaceutical Sciences Translational MedicinePharmacokinetic ModelingPart 2Prediction MethodsMedicine	2011	133
Performance qualification of a new hypromellose capsule: Part I. Comparative evaluation of physical, mechanical and processability quality attributes of Vcaps Plus®, Quali-V® and gelatin capsules M. Sherry Ku, Weiyi Li, Wendy Dulin, International Journal of Pharmaceutics New Hypromellose CapsulePerformance QualificationGelatin CapsulesBiomedical EngineeringMedicine	2009	78
PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets Patrick Poulin, Hannah M. Jones, Rhys D.O. Jones, Journal of Pharmaceutical Sciences Part 1Pharmacokinetic ModelingPharmacologyPhrma Cpcdc InitiativePhrma Dataset	2011	60
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach Ragini Vuppugalla, Punit Marathe, Handan He, Journal of Pharmaceutical Sciences Precision DosingTherapeutic Drug MonitoringPharmacokinetic ModelingPreclinical Drug EvaluationMedicine	2011	59
Solid dispersion of acetaminophen and poly(ethylene oxide) prepared by hot-melt mixing Min Yang, Peng Wang, Chien-Yueh Huang, International Journal of Pharmaceutics Materials ScienceChemical EngineeringEngineeringPolymer SciencePolymer Blend	2010	57
Performance qualification of a new hypromellose capsule: Part II. Disintegration and dissolution comparison between two types of hypromellose capsules M. Sherry Ku, Qinghong Lu, Weiyi Li, International Journal of Pharmaceutics Dissolution ComparisonHypromellose CapsulesMedicinePerformance QualificationBiomedical Engineering	2011	40

Page 1